1. TGF-beta/Smad
  2. TGF-β Receptor
  3. LSKL, Inhibitor of Thrombospondin TSP-1

LSKL, Inhibitor of Thrombospondin TSP-1 

Cat. No.: HY-P0299 Purity: 98.46%
Handling Instructions

LSKL, Inhibitor of Thrombospondin (TSP-1) is a peptide derived from the latency-associated peptide, inhibits thrombospondin (TSP-1) activation of TGF-β and prevents the progression of hepatic damage and fibrosis.

For research use only. We do not sell to patients.

Custom Peptide Synthesis

LSKL, Inhibitor of Thrombospondin TSP-1 Chemical Structure

LSKL, Inhibitor of Thrombospondin TSP-1 Chemical Structure

CAS No. : 283609-79-0

Size Price Stock Quantity
10 mM * 1 mL in DMSO USD 119 In-stock
Estimated Time of Arrival: December 31
5 mg USD 108 In-stock
Estimated Time of Arrival: December 31
10 mg USD 156 In-stock
Estimated Time of Arrival: December 31
25 mg USD 312 In-stock
Estimated Time of Arrival: December 31
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

Customer Review

Based on 2 publication(s) in Google Scholar

Top Publications Citing Use of Products

Publications Citing Use of MCE LSKL, Inhibitor of Thrombospondin TSP-1

  • Biological Activity

  • Protocol

  • Purity & Documentation

  • References

  • Customer Review

Description

LSKL, Inhibitor of Thrombospondin (TSP-1) is a peptide derived from the latency-associated peptide, inhibits thrombospondin (TSP-1) activation of TGF-β and prevents the progression of hepatic damage and fibrosis.

In Vitro

LSKL peptide is able to reduce liver fibrosis by inhibiting TGF-β activation[2].

In Vivo

LSKL (1 mg/kg, i.p.) can easily traverse the blood brain barrier. LSKL peptide also alleviates hydrocephalus and improves long-term cognitive function following SAH. Moreover, LSKL peptide inhibits subarachnoid fibrosis after SAH. LSKL treatment significantly decreases the activation of TGF-β1 in the CSF in comparison with that in the SAH+PBS group[1]. LSKL peptide (30 mg/kg, i.p.) successfully inhibits transforming growth factor (TGF) β-Smad signal activation induced by partial hepatectomy. LSKL peptide successfully attenuates TGF-β-Smad signal activation by antagonizing TSP-1, but not by reducing TSP-1 protein expression. LSKL peptide accelerates hepatocyte proliferation after hepatectomy[3].

Molecular Weight

458.60

Formula

C₂₁H₄₂N₆O₅

CAS No.

283609-79-0

Sequence

Leu-Ser-Lys-Leu

Sequence Shortening

LSKL

Shipping

Room temperature in continental US; may vary elsewhere.

Storage
Powder -80°C 2 years
  -20°C 1 year
In solvent -80°C 6 months
  -20°C 1 month
Solvent & Solubility
In Vitro: 

DMSO : ≥ 100 mg/mL (218.05 mM)

H2O : 50 mg/mL (109.03 mM; Need ultrasonic)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.1805 mL 10.9027 mL 21.8055 mL
5 mM 0.4361 mL 2.1805 mL 4.3611 mL
10 mM 0.2181 mL 1.0903 mL 2.1805 mL
*Please refer to the solubility information to select the appropriate solvent.
In Vivo:
  • 1.

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.5 mg/mL (5.45 mM); Clear solution

  • 2.

    Add each solvent one by one:  10% DMSO    90% corn oil

    Solubility: ≥ 2.5 mg/mL (5.45 mM); Clear solution

*All of the co-solvents are provided by MCE.
References
Animal Administration
[3]

Wild-type 8–12-week-old male mice (C57BL/6) are used for all experiments. LSKL TSP-1 inhibitory peptide is diluted to 5 mg/mL with normal saline. In the LSKL peptide group, LSKL peptide (30 mg/kg bodyweight in 6 mL/kg) is administered intraperitoneally before abdominal wall closure and at 6 h after the 70 per cent hepatectomy. In the normal saline group, saline (6 mL/kg) is given intraperitoneally at the same time points. In the sham-operated group, laparotomy is performed and the incision is sutured after normal saline (6 mL/kg) have been administered intraperitoneally.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2

Keywords:

LSKL, Inhibitor of Thrombospondin TSP-1TGF-β ReceptorTransforming growth factor beta receptorsInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product name

 

Salutation

Applicant name *

 

Email address *

Phone number *

 

Organization name *

Country or Region *

 

Requested quantity *

Remarks

Bulk Inquiry

Inquiry Information

Product name:
LSKL, Inhibitor of Thrombospondin TSP-1
Cat. No.:
HY-P0299
Quantity:
MCE Japan Authorized Agent: